by Instem Team | Mar 26, 2026 | Clinical
Open-source software has transformed how life sciences organizations approach analytics. Tools such as R offer flexibility, rapid innovation, and a rich diversity of community-developed packages. However, open-source adoption in regulated clinical environments comes...
by Instem Team | Mar 25, 2026 | In Silico & Data Insights, Regulatory Submission, Study Management
Preclinical Efficacy Preclinical efficacy studies serve as a key bridge between discovery and the later stages of drug development. These studies examine the mechanism of action and efficacy of lead compounds against disease models. This is a pivotal translation...
by Instem Team | Mar 18, 2026 | Clinical
Open-source technology has reshaped nearly every data-driven industry, including the life sciences. Among open-source tools, R has emerged as a strong choice for modern biostatistics, clinical analytics, and research. The flexibility, vast package availability, and...
by Instem Team | Mar 18, 2026 | In Silico & Data Insights, Regulatory Submission, Study Management
Lead Optimization Once a selection of hits has been identified, the process of drug discovery moves to refine initial hits with promising biological activity into validated leads that are optimized for potency, selectivity, and drug-like properties. Lead optimization...
by Instem Team | Mar 15, 2026 | Resources
Vivarium managers and research staff face increasing pressure to maintain well‑organized, compliant, and high‑integrity colony data while supporting fast‑paced research timelines. Legacy spreadsheets and disconnected tools make it difficult to track breeding programs,...
